PE20070235A1 - Vacuna que contiene rotavirus atenuado - Google Patents

Vacuna que contiene rotavirus atenuado

Info

Publication number
PE20070235A1
PE20070235A1 PE2006000993A PE2006000993A PE20070235A1 PE 20070235 A1 PE20070235 A1 PE 20070235A1 PE 2006000993 A PE2006000993 A PE 2006000993A PE 2006000993 A PE2006000993 A PE 2006000993A PE 20070235 A1 PE20070235 A1 PE 20070235A1
Authority
PE
Peru
Prior art keywords
rotavirus
vaccine containing
refers
sequence
attenuated rotavirus
Prior art date
Application number
PE2006000993A
Other languages
English (en)
Inventor
Brigitte Desiree Alberte Colau
Vos Beatrice Arsene Virginie De
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0516944A external-priority patent/GB0516944D0/en
Priority claimed from GB0521164A external-priority patent/GB0521164D0/en
Priority claimed from GB0608962A external-priority patent/GB0608962D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of PE20070235A1 publication Critical patent/PE20070235A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

SE REFIERE A UNA COMPOSICION INMUNOGENICA QUE COMPRENDE UNA CEPA DE ROTAVIRUS ATENUADO DE UN TIPO GxPy, EN DONDE DICHO ROTAVIRUS CONTIENE UN GEN VP4 QUE COMPRENDE EN LA SECUENCIA DE NUCLEOTIDOS AL MENOS: UNA ADENINA (A) EN LA POSICION 788, O EN LA POSICION 802, Y UNA BASE TIMINA (T) EN LA POSICION 501 DESDE EL CONDON DE PARTIDA; Y UN GEN VP7 QUE COMPRENDE EN LA SECUENCIA DE NUCLEOTIDOS AL MENOS UNA TIMINA (T) EN POSICION 605, UNA ADENINA EN LA POSICION Y UNA GUANINA (G) EN LA POSICION 897. TAMBIEN SE REFIERE A UN PROCEDIMIENTO. DICHA COMPOSICION GENERA UN ARESPUESTA INMUNE CONTRA UNA CEPA DE ROTAVIRUS QUE NI ES DE TIPO Gx NI Py, PROPORCIONANDO ASI PROTECCION CONTRA ENTEROCOLITIS PROVOCADA POR ROTAVIRUS
PE2006000993A 2005-08-17 2006-08-15 Vacuna que contiene rotavirus atenuado PE20070235A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0516944A GB0516944D0 (en) 2005-08-17 2005-08-17 Vaccine
GB0521164A GB0521164D0 (en) 2005-10-18 2005-10-18 Vaccine
GB0608962A GB0608962D0 (en) 2006-05-05 2006-05-05 Vaccine

Publications (1)

Publication Number Publication Date
PE20070235A1 true PE20070235A1 (es) 2007-04-04

Family

ID=37757924

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000993A PE20070235A1 (es) 2005-08-17 2006-08-15 Vacuna que contiene rotavirus atenuado

Country Status (25)

Country Link
US (1) US20090028828A1 (es)
EP (2) EP2233153B1 (es)
JP (1) JP5519934B2 (es)
KR (1) KR20080036648A (es)
AR (1) AR054916A1 (es)
AU (1) AU2006281566B2 (es)
BR (1) BRPI0615203A2 (es)
CA (1) CA2619751C (es)
CR (1) CR9759A (es)
CY (1) CY1116135T1 (es)
DK (1) DK2233153T3 (es)
EA (1) EA014328B1 (es)
ES (1) ES2534637T3 (es)
HR (1) HRP20150310T1 (es)
IL (1) IL189289A0 (es)
MA (1) MA29700B1 (es)
MX (1) MX2008002270A (es)
NO (1) NO20080754L (es)
PE (1) PE20070235A1 (es)
PL (1) PL2233153T3 (es)
PT (1) PT2233153E (es)
SG (1) SG163571A1 (es)
SI (1) SI2233153T1 (es)
TW (1) TW200740457A (es)
WO (1) WO2007020078A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0107510D0 (en) 2001-03-26 2001-05-16 Univ Bristol New elongase gene and a process for the production of -9-polyunsaturated fatty acids
EP2197283B1 (en) * 2007-09-25 2013-07-17 Aridis Pharmaceuticals Formulations for preservation of rota virus
US9311112B2 (en) * 2009-03-16 2016-04-12 Apple Inc. Event recognition
EP2701735A4 (en) * 2011-04-28 2014-11-26 Internat Medica Foundation LIQUID VACCINE COMPOSITIONS
CN104507495A (zh) * 2012-04-23 2015-04-08 巴拉特生物技术国际有限公司 轮状病毒疫苗组合物及其制备方法
WO2017062246A1 (en) 2015-10-05 2017-04-13 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human rota virus g9p[6] strain and use as a vaccine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0557427B1 (en) * 1990-11-16 1998-08-26 Children's Hospital Medical Center Human rotaviruses, vaccines and methods
HU228975B1 (en) * 1999-08-17 2013-07-29 Smithkline Beecham Biolog Vaccine
PL1660123T3 (pl) * 2003-09-02 2013-08-30 Glaxosmithkline Biologicals Sa Szczepionka rotawirusowa

Also Published As

Publication number Publication date
PT2233153E (pt) 2015-04-20
KR20080036648A (ko) 2008-04-28
SG163571A1 (en) 2010-08-30
JP5519934B2 (ja) 2014-06-11
BRPI0615203A2 (pt) 2011-05-10
MX2008002270A (es) 2008-03-27
EP2233153A1 (en) 2010-09-29
TW200740457A (en) 2007-11-01
SI2233153T1 (sl) 2015-05-29
WO2007020078A3 (en) 2007-05-24
CY1116135T1 (el) 2017-02-08
AU2006281566B2 (en) 2011-09-01
AR054916A1 (es) 2007-07-25
WO2007020078A2 (en) 2007-02-22
CR9759A (es) 2008-05-05
EA014328B1 (ru) 2010-10-29
ES2534637T3 (es) 2015-04-27
EA200800320A1 (ru) 2008-10-30
PL2233153T3 (pl) 2015-06-30
HRP20150310T1 (hr) 2015-06-19
EP2233153B1 (en) 2015-01-21
MA29700B1 (fr) 2008-08-01
IL189289A0 (en) 2008-06-05
JP2009504701A (ja) 2009-02-05
AU2006281566A1 (en) 2007-02-22
NO20080754L (no) 2008-05-15
US20090028828A1 (en) 2009-01-29
CA2619751A1 (en) 2007-02-22
EP1915173A2 (en) 2008-04-30
DK2233153T3 (da) 2015-04-27
CA2619751C (en) 2016-07-05

Similar Documents

Publication Publication Date Title
PE20070235A1 (es) Vacuna que contiene rotavirus atenuado
Menachery et al. Combination attenuation offers strategy for live attenuated coronavirus vaccines
Vignuzzi et al. Engineering attenuated virus vaccines by controlling replication fidelity
PE20110998A1 (es) Oligonucleotidos inmunoestimuladores
BRPI0410702A (pt) polinucleotìdeo isolado, composição, métodos para preparar um vìrus de influenza e um veìculo de liberação de genes, e para imunizar um indivìduo contra um patógeno, vìrus, célula, e, vetor
MY163972A (en) Attenuated recombinant newcastle disease virus and vaccine containing the same
AR053913A1 (es) Cepa atenuada de dengue serotipo 1
BR0211492A (pt) Vacina para west nile
CO6290703A2 (es) Vacunas que contienen variantes genericas de parvovirus canino
AR049825A1 (es) Vacuna de una subunidad prrsv
TW200726479A (en) Method of inducing neutralizing antibodies to human immunodeficiency virus
HRP20160299T1 (hr) Cjepivo protiv rotavirusa
WO2003076591A3 (en) Compositions and methods for generating an immune response
AR059005A1 (es) Virus quimericos del dengue
CO6351810A2 (es) Vacunas contra la bronquitis infecciosa derivadas de cepas similares a qx-bi
ES2585242T3 (es) Cepas virales obtenidas del virus vaccinia Lister VACV-107 y usos de las mismas
GB2429711A (en) Heart and skeletal muscle inflammation (HSMI) virus
Chen Molecular evolution and epidemiology of four serotypes of dengue virus in Thailand from 1973 to 2007
MX2021000949A (es) Nueva cepa de virus atenuada y su uso como una vacuna.
Bishop-Lilly et al. Genome sequencing of 15 clinical Vibrio isolates, including 13 non-O1/non-O139 serogroup strains
Domingo et al. Mutation, quasispecies, and lethal mutagenesis
Elebesunu et al. Attaining the balance between wild poliovirus eradication and vaccine-derived poliovirus control
Scott et al. Murine cytomegalovirus resistant to antivirals has genetic correlates with human cytomegalovirus
WO2010135054A3 (en) Mutations in a toll-like receptor motif in the ns4b of classical swine fever virus skin brescia influences virulence in swine
WO2009069447A1 (ja) インフルエンザワクチン用のアジュバント及びインフルエンザワクチン

Legal Events

Date Code Title Description
FC Refusal